Mapeamento de fatores clínicos preditivos da neuropatia sensorial periférica induzida por oxaliplatina: revisão sistemática
DOI:
10.24276/rrecien2021.11.35.382-397Palavras-chave:
Toxicidade, Quimioterapia Combinada, Enfermagem Baseada em Evidências, Cuidados de Enfermagem, Neoplasias ColorretaisResumo
O objetivo deste estudo foi realizar um mapeamento dos fatores clínicos preditivos da Neuropatia Sensorial Periférica induzida pela Oxaliplatina. Para tanto, foi realizada uma revisão sistemática, elaborada a partir das recomendações da diretriz PRISMA. A estratégia PICO também foi utilizada para formular a questão de pesquisa e orientar a busca nas bases de dados: PubMed, Embase, Scopus, BVS/IBECS e CINAHL. Foram selecionadas 26 publicações para análise final e inclusão na revisão. As publicações foram classificadas quanto ao nível de evidência e grau de recomendação, de acordo com o sistema JBI. Na análise das publicações foram mapeados 15 fatores preditivos, com maior destaque para a dose cumulativa de Oxaliplatina utilizada. O reconhecimento dos fatores clínicos preditivos da Neuropatia Sensorial Periférica, independente da precocidade que possa ser feito, são importantes para a elaboração de estratégias mensuráveis no exercício do cuidado colaborativo e multidimensional.
Downloads
Referências
Torres M, Khan S, Duplanty M, et al. Raman and infrared studies of platinum-based drugs: cisplatin, carboplatin, oxaliplatin, Nedaplatin, and Heptaplatin. J Phys Chem A. 2018; 122(34):6934-6952.
Galan-Ros J, Ramos-Arenas V, Conesa-Zamora P. Predictive values of colon microbiota in the treatment response to colorectal cancer. Pharmacogenomics. 2020; 21(14):138-145.
Muhammad IQ, Saba G. Awareness about intestinal cancer in university student. Nov Approaches Cancer Study. 2018; 1(3):95-97.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA: Cancer J Clin. 2020; 70:7-3.
INCA. Instituto Nacional de Câncer. Estatísticas de câncer. Brasília: Ministério da Saúde, 2020. <https://www.inca.gov.br/>. Accessed Out. 2020.
Varadhachary GR, Hoff PM. Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy. Semin Oncol. 2005; 32(supl. 9):40-42.
Hoff PM, Ellis LM, Abbruzzese JL. Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? Oncol (Huntingt). 2004; 18(6):736-741.
Andre T, Boni C, Mounedji‐Boudiaf L, et al. fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350:2343-2351.
Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first‐line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-2947.
Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal câncer. Int J Cancer. 2011; 128(3):682-90.
Boscato SC, Godoy MR, Heineck I. Xelox Versus Folfox no tratamento do câncer colorretal: Revisão de estudos farmacoeconômicos. [Xelox Versus Folfox in the treatment of colorectal cancer: Review of pharmacoeconomic studies]. Value Health. 2017; 20(9):A853-A943.
Misra UK, Kalita J, Nair PP. Diagnostic approach to peripheral neuropathy. Ann Indian Acad Neurol. 2008; 11(2):89-97.
Costa TC, Lopes M, Anjos ACY, Zago MMF. Neuropatia periférica induzida pela quimioterapia: revisão integrativa da literatura. Rev Esc Enferm USP. 2015; 49(2):335-45.
Cavaletti G, Cornblath DR, Merkies ISJ, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol. 2013; 24(2):454-462.
Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin - induced peripheral nerve hyperexcitability. J Clin Oncol. 2002; 20(7):1767-1774.
National Cancer Institute. Fact Book. 2010. <https://www.cancer.gov/about-nci/budget/fact-book/archive/2010-fact-book.pdf>. Acesso em 10 jul 2020.
Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-269.
Joanna Briggs Institute. JBI approach to evidence-based healthcare. 2014. <http://joannabriggs.org/jbi-approach.html#tabbe d-nav=Levels-of-Evidence>. Acesso em 10 jul 2020.
Bano N, Ikram R. Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens. Pak J pharm Sci. 2019; 32(1):249-253.
Soveri LM, Lamminmäki A, Hänninen UA, Karhunen M, Bono P, Osterlund P. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncol. 2019; 58(4):398-406.
Abdel-Rahman O. Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies. Clin Transl Oncol. 2019; 21(4):512-518.
Gebremedhn EG, Shortland PJ, Mahns DA. Variability of Oxaliplatin-Induced Neuropathic Pain Symptoms in Each Cycle and Its Implications on the Management of Colorectal Cancer Patients: A Retrospective Study in South Western Sydney Local Health District Hospitals, Sydney, Australia. J Oncol. 2019; 4828563.
Wesselink E, Winkels RM, Van Baar H, et al. Dietary intake of magnesium or calcium and chemotherapy-induced peripheral neuropathy in colorectal cancer patients. Nutrients. 2018; 10(4): 398-402.
Hsu SY, Huang WS, Lee SH, et al. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin‐induced peripheral neuropathy in Taiwanese patients with colorectal cancer. Eur J Cancer Care. 2019; 28(2):e12976.
Cassinello J, Serrano C, De Mon MA. Clinical and neurophysiologic prospective study with time-event and long-term analysis of the chronic neurotoxicity associated with oxaliplatin in patients with colorectal cancer (CRC). J Clin Oncol. 2017; 35(15):e15150-e15150.
Raphael MJ, Fischer HD, Fung K. Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer. Clin Colorectal Cancer. 2017; 16(4):397-404.
Palugulla S, Thakkar DN, Kayal S, Narayan SK, Dkhar SA. Association of Voltage-Gated Sodium Channel Genetic Polymorphisms with Oxaliplatin-Induced Chronic Peripheral Neuropathy in South Indian Cancer Patients. Asian Pac J Cancer Prev. 2017; 18:3157–3165.
Reddy SM, Vergo MT, Paice JA, et al. Quantitative sensory testing at baseline and during cycle 1 oxaliplatin infusion detects subclinical peripheral neuropathy and predicts clinically overt chronic neuropathy in gastrointestinal malignancies. Clin Colorectal Cancer. 2016; 15(1):37-46.
Tanishima H, Tominaga T, Kimura M, Maeda T, Shirai Y, Horiuchi T. Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy. Suppor Care Cancer. 2017; 25(5):1383-1389.
Ottaiano A, Nappi A, Tafuto S, et al. Diabetes and body mass index are associated with neuropathy and prognosis in colon cancer patients treated with capecitabine and oxaliplatin adjuvant chemotherapy. Oncology. 2016; 90(1):36-42.
Wang XS, Shi Q, Dougherty PM, et al. Prechemotherapy touch sensation deficits predict oxaliplatin-induced neuropathy in patients with colorectal cancer. Oncology. 2016; 90(3):127-135.
Altaf R, Brixen AL, Kristensen B, Nielsen SE. Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. Oncology. 2014; 87(3):167-172.
Velasco R, Bruna J, Briani C, et al. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry. 2014; 85(4):392-398.
Vincenzi B, Frezza AM, Schiavon G, et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care in Cancer. 2013; 21(5):1313-1319.
Alejandro L, Behrendt CE, Chen K, Openshaw H, Shibata S. Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol. 2013; 36(4):331-336.
Sugihara K, Ohtsu A, Shimada Y, et al. Analysis of neurosensory adverse events induced by FOLFOX 4 treatment in colorectal cancer patients: a comparison between two A sian studies and four W estern studies. Cancer Med. 2012; 1(2):198-206.
Uwah AN, Ackler J, Leighton Jr JC, Pomerantz S, Tester W. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer. 2012; 11(4):275-279.
Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011; 12(7):642-653.
Hill A, Bergin P, Hanning F, et al. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer. 2010; 10(1):451-456.
Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. PAIN®. 2009; 144(3):245-252.
Aprile G, Ramoni M, Keefe D, Sonis S. Acute toxicities in colorectal cancer (CRC) patients undergoing chemotherapy (CT): Clustering and cycle-to-cycle prediction by means of Bayesian analysis. In: Annals of Oncology, v. 18, pp. 12. Great Clarendon ST, Oxford OX2 6DP, England: Oxford Univ Press. 2007.
Mattioli R, Massacesi C, Recchia F, et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol. 2005; 16(7):1147-1151.
Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin‐induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005; 32(1):51-60.
Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000; 18(1):136-140.
Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990; 25:299-303.
Pulvers JN, Marx G. Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review. Asia-Pac J Clin Oncol. 2017; 13:345-55.
Volpe SL. Magnesium in disease prevention and overall health. Adv Nutr. 2013; 4(3):378S-83S.
Aminoff MJ. Neurology and General Medicine. 4th. ed. New York: Churchill Livingstone. 2007.
Publicado
- Visualizações 0
- PDF downloads: 0
